Humane Genomics
A platform to make artificial viruses as cancer therapeutics.
About
Humane Genomics has developed a platform to engineer cancer killing viruses. We have taken a first principles approach to design and make oncolytic viral therapies. Using a highly lytic RNA virus engineered with "2 factor authentication" (using selective infection and selective replication) they have an on-target to off-target kill ratio > 1000. We are working on our first indication, pediatric liver cancer (hepatoblastoma), with our partners at Texas Children's Hospital, who are world leading experts. We have in vivo (mouse) data showing safety and currently developing efficacy data and are showing 50% reduction in tumor volume.
Topics
- Location
- New York, NY, United States
- Team size
- 5 employees
- YC batch
- Summer 2021
- Status
- Active
- Stage
- Early stage
